Literature DB >> 17594714

Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.

Matthew K Tollefson1, R Houston Thompson, Yuri Sheinin, Christine M Lohse, John C Cheville, Bradley C Leibovich, Eugene D Kwon.   

Abstract

BACKGROUND: Ki-67 is a cell proliferation protein associated with aggressive clear cell renal cell carcinoma (ccRCC). A recent report suggests that Ki-67 may represent a surrogate marker for coagulative tumor necrosis. Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC.
METHODS: Tumor specimens from 741 consecutively treated patients who underwent surgery for ccRCC between 1990 and 1999 were evaluated. Tumor specimens were assessed for various clinicopathologic features, including levels of tumor cell Ki-67 expression. Associations of these features with death from RCC were evaluated using Cox proportional hazards regression models.
RESULTS: At last follow-up, 396 patients had died, including 238 who died from ccRCC at a median of 2.1 years after surgery. Although tumor cell Ki-67 expression and coagulative tumor necrosis were highly correlated, the prognostic information conveyed by these 2 markers failed to overlap. For the subset of patients with necrotic tumors, high levels of Ki-67 more than doubled the risk of death from RCC (risk ratio, 2.18; 95% confidence interval [CI], 1.52-3.11; P < .001). For patients with tumors lacking necrosis, high levels of Ki-67 expression were similarly correlated with an increased risk of death from RCC (risk ratio, 2.50; 95% CI, 1.66-3.77; P < .001).
CONCLUSIONS: Prognostic information conveyed by Ki-67 and coagulative tumor necrosis are not interchangeable. Thus, Ki-67 and coagulative tumor necrosis should not be treated as surrogates for one another and both of these features should be evaluated when generating outcome predictions for patients with ccRCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594714     DOI: 10.1002/cncr.22840

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Predicting biological behaviour of newly diagnosed renal masses: a possible role of cell proliferation biomarkers?

Authors:  Riccardo Mastroianni; Aldo Brassetti; Manuela Costantini; Giuseppe Simone
Journal:  Ann Transl Med       Date:  2019-07

2.  Renal Tumours in Adults with Correlation between Fuhrman Grading and Proliferative Marker.

Authors:  Sabuj Ghana Mukhopadhyay; Krishnendu Mukherjee; Asim Kr Manna
Journal:  Iran J Pathol       Date:  2015

Review 3.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

4.  Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies.

Authors:  Constantinos T Sofocleous; Sandeep Garg; Lydia M Petrovic; Mithat Gonen; Elena N Petre; David S Klimstra; Stephen B Solomon; Karen T Brown; Lynn A Brody; Ann M Covey; Ronald P Dematteo; Lawrence Schwartz; Nancy E Kemeny
Journal:  Ann Surg Oncol       Date:  2012-07-03       Impact factor: 5.344

5.  Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.

Authors:  Alexander S Parker; Bradley C Leibovich; Christine M Lohse; Yuri Sheinin; Susan M Kuntz; Jeanette E Eckel-Passow; Michael L Blute; Eugene D Kwon
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

6.  Tissue microarrays: one size does not fit all.

Authors:  Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon
Journal:  Diagn Pathol       Date:  2010-07-07       Impact factor: 2.644

7.  Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression.

Authors:  E Jason Abel; Tyler M Bauman; Madelyn Weiker; Fangfang Shi; Tracy M Downs; David F Jarrard; Wei Huang
Journal:  Hum Pathol       Date:  2014-01-28       Impact factor: 3.466

8.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.

Authors:  Nathan E Hoffmann; Yuri Sheinin; Christine M Lohse; Alexander S Parker; Bradley C Leibovich; Zhong Jiang; Eugene D Kwon
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

Review 9.  Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.

Authors:  Yuan-Mao Lin; Ryosuke Taiji; Marco Calandri; Bruno C Odisio
Journal:  Curr Oncol Rep       Date:  2021-04-15       Impact factor: 5.075

10.  Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma.

Authors:  Jinbo Song; Zhe Yu; Bingqi Dong; Mingkai Zhu; Xiaofeng Guo; Yongkang Ma; Shiming Zhao; Tiejun Yang
Journal:  World J Surg Oncol       Date:  2021-05-25       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.